4,005
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study

, , , , , , , , , , , , , , , , , , , , & show all
Pages 3540-3547 | Received 21 Mar 2019, Accepted 02 Jul 2019, Published online: 22 Aug 2019

Figures & data

Figure 1. Study design diagram (a) and basic information of withdraw (b).

Figure 1. Study design diagram (a) and basic information of withdraw (b).

Table 1. SLIT Dosing schedule.

Table 2. Baseline characteristics of the patients.

Table 3. Baseline skin prick test results.

Figure 2. Mean SCORAD over 36-weeks’ treatment period. (a) Mean SCORAD in FAS; (b) Mean SCORAD in PPS. *p < .05.

Figure 2. Mean SCORAD over 36-weeks’ treatment period. (a) Mean SCORAD in FAS; (b) Mean SCORAD in PPS. *p < .05.

Table 4. Clinical efficacy rate.

Figure 3. Mean medication score from fourth to sixth follow-up. Medication score was calculated in every follow-up by days of concomitant drugs use. Every single day use of one kind of concomitant drug represented one point. (a) Mean total medication score in FAS. (b) Mean total medication score in PPS. (c) Mean topical glucocorticoids medication score in FAS. (d) Mean topical glucocorticoids medication score in PPS.

Figure 3. Mean medication score from fourth to sixth follow-up. Medication score was calculated in every follow-up by days of concomitant drugs use. Every single day use of one kind of concomitant drug represented one point. (a) Mean total medication score in FAS. (b) Mean total medication score in PPS. (c) Mean topical glucocorticoids medication score in FAS. (d) Mean topical glucocorticoids medication score in PPS.

Figure 4. Skin lesion area score from first to sixth follow-up. (a) Skin lesion area score in FAS. (b) Skin lesion area score in PPS. *p < .05.

Figure 4. Skin lesion area score from first to sixth follow-up. (a) Skin lesion area score in FAS. (b) Skin lesion area score in PPS. *p < .05.

Figure 5. Dermatology life quality index (DLQI). (a) DLQI in first (baseline), fourth and sixth follow-ups in FAS. (b) DLQI in first (baseline), fourth and sixth follow-ups in PPS.

Figure 5. Dermatology life quality index (DLQI). (a) DLQI in first (baseline), fourth and sixth follow-ups in FAS. (b) DLQI in first (baseline), fourth and sixth follow-ups in PPS.

Table 5. Incidence of adverse drug reaction.

Table 6. Number and severity of adverse drug reaction.